Introduction: Although international clinical practice guidelines recognize a continued role
for menopausal hormone therapy (HT), particularly for symptomatic women< 60 years of age …

Background Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the
treatment of vasomotor symptoms in menopausal women as options are scarce for those …

Given the critical central role of gonadotropin‐releasing hormone (GnRH) neurons in fertility,
it is not surprising that the GnRH neural network is implicated in the pathology of polycystic …

The British Menopause Society & Women’s Health Concern 2020 recommendations on
hormone replacement therapy in menopausal women - Haitham Hamoda, Nick Panay …

Context Polycystic ovary syndrome (PCOS), a highly prevalent endocrine disorder
characterized by hyperandrogenism, is the leading cause of anovulatory infertility. Objective …

Background: Over 75% of menopausal women experience vasomotor symptoms (VMS),
such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is …

This systematic review and meta-analysis investigated the efficacy and safety of fezolinetant
for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with …

OBJECTIVE: To evaluate the efficacy and adverse events of fezolinetant for treating
vasomotor symptoms (VMS) of menopause. DATA SOURCES: PubMed/MEDLINE …

Background Postmenopausal women are more likely to experience vasomotor symptoms
(VMS), such as heat sensation and sweating. Recent trials have investigated fezolinetant in …

The tachykinin neuropeptide of neurokinin B (NKB) is a copper-binding amyloid peptide with
important roles in the regulation of physiological functions and pathophysiological …